After 12 weeks of nebulized NAC, patients’ mean phlegm scores, as measured by the COPD assessment test, significantly decreased from 3.47 at baseline to 2.62. N-acetylcysteine (NAC) nebulizer ...

The NE-U22V MicroAir®, the world’s smallest nebulizer utilizing Vibrating Mesh Technology (V.M.T.), efficiently delivers solution medications for patients suffering from asthma, COPD or other ...

The Model 646 Nebulizer converts liquid into aerosol via ... it delivers consistent aerosol particles to the lungs of COPD patients.

Treatment with Ohtuvayre in COPD was linked to improved lung function and other benefits across key patient subgroups in ...

An agreement on L606, a slow-release formulation of inhaled treprostinil now in a Phase 3 trial, was extended by Pharmosa and ...

COPD may require a lot more planning ... The good news is that your medical supplies, such as nebulizers, concentrators, and batteries do not count against your carry-on limit so you can take ...

It is the first inhaled product with a novel mechanism of action available for the maintenance treatment of COPD in more than 20 years. Ohtuvayre is delivered through a standard jet nebulizer and ...

MannKind's (MNKD) stock surged 73%, driven by its 9% royalty stake in Tyvaso DPI. It has strong liquidity. Click here to see ...

Liquidia amends exclusive license to include key markets in Europe, Japan and elsewhereLiquidia also obtains rights to Pharmosa’s next-generation ...

N-acetylcysteine (NAC) nebulizer therapy is effective and safe in the short-term (12 weeks) for reducing phlegm in COPD.

Liquidia, Pharmosa Biopharm expand collaboration to develop sustained release inhaled treprostinil: Morrisville, North Carolina Friday, October 4, 2024, 16:00 Hrs [IST] Liquidia C ...